Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Sequential Administration of Anti-Complement Component C5 Eculizumab and Type-2 Anti-Cd20 Obinutuzumab for the Treatment of Early Antibody-Mediated Rejection after Kidney Transplantation: A Proof of Concept

Evaldo Favi,Donata Cresseri,Marta Perego,Masami Ikehata,Samuele Iesari,Maria Rosaria Campise,William Morello,Sara Testa,Viviana Sioli,Deborah Mattinzoli,Elena Longhi,Alessandro Del Gobbo,Giuseppe Castellano,Mariano Ferraresso

CLINICAL IMMUNOLOGY（2024）

Cited 0|Views26
Key words
Obinutuzumab,Eculizumab,Antibody -mediated rejection,Kidney transplant,Immunosuppression,Treatment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined